血塞通注射液联合阿加曲班注射液治疗进展性脑梗死的临床疗效观察

目的观察血塞通注射液联合阿加曲班注射液治疗进展性脑梗死的临床疗效。方法2010年12月-2012年12月在南阳市唐河县人民医院住院的进展性脑梗死患者80例随机分为治疗组（40例）和对照组（40例）。两组患者均针对颅内压升高情况给予脱水剂，给予胞二磷胆碱、脑细胞保护剂，同时视血压、血糖情况给予适当的降糖和控制血压等一般治疗。对照组在一般治疗基础上给予血塞通注射液0．4g加入5％葡萄糖注射液或生理盐水250mL中静脉滴注，1次／d。治疗组给予阿加曲班注射液，第1、2天每天用阿加曲班60mg，以500mL生理盐水稀释，24h持续静脉滴注；其后5d每天用阿加曲班10mg以100mL生理盐水稀释，分早晚2次持续静脉滴注，每次3h，其他同对照组，两组均连续治疗14d。观察两组患者治疗前后神经功能缺损评分和日常生活活动能力改变情况。结果两组治疗14d后与治疗前比较神经功能缺损评分均明显降低，差异有统计学意义（P〈0．05），治疗后，治疗组较对照组降低更明显（P〈0．05）；两组治疗后日常生活活动能力评分较治疗前均明显提高，治疗前后差异有统计学意义（P〈0．05），且治疗后治疗组高于对照组（P〈0．05）。治疗组与对照组总有效率分别为95．0％、77．5％，两组比较差异有统计学意义（P〈0．05）。两组均无不良反应发生。结论血塞通注射液联合阿加曲班注射液能够显著改善进展性脑梗死患者的神经功能缺损症状，提高日常生活活动能力，疗效显著。

Clinical observation of Xuesaitong Injection combined with Argatroban Injection in treatment of progressive cerebral infarction

Objective To evaluate the clinical efficacy of Xuesaitong Injection combined with Argatroban Injection in the treatment of progressive cerebral infarction. Methods The patients （80 cases） diagnosed as progressive cerebral infarction in People＇s Hospital of Tanghe County in Nanyang City fi＇om December 2010 to December 2012 were randomly divided into treatment （40 cases） and control （40 cases） groups. The patients were given dehydrant according to the increased intracranial pressure, and were given protective agent for brain cells, and were given the blood pressure controlling and hypoglycemic treatment according to the level of blood pressure and blood glucose. Based on the general treatment, patients in the control group were iv administered with Xuesaitong Injection （0.4 g） which was diluted with 5% glucose injection or physiological saline （250 mL）, once daily. In addition, the patients in the treatment group were treated with Argatroban Injection （60 mg diluted with 500 mL physiological saline） through 24 h continuous iv pump infusion on the first 2 d. The next 5 d they were treated with Argatroban Injection （10 mg diluted with 100 mL physiological saline）, through continuous 3 h iv infusion twice daily in the morning and evening, other was the same as the control group. The patients in the two groups were treated for 14 d. The changes of neurological function and activities of daily living were observed in the two groups before and after treatment. Results Within 14 d after the treatment, the neural function defect scores of the patients in the two groups were significantly lower than those before the treatment （P 〈 0.05）, and the difference between the two groups was statistically significant （P 〈 0.05）. The activities of daily living capacity score after the treatment in the two groups were significantly higher than those before the treatment （P 〈 0.05）, and the difference between the two groups was statistically significant （P 〈 0.05）. The efficiencies for the patients both in the treatment and control groups were 95.0% and 77.5% with the significant difference （P 〈 0.05）. There was no adverse drug reaction in the two groups. Conclusion Xuesaitong Injection combined with Argatroban Injection could significantly improve the neurological function and activities of daily living capacity in the patients with progressive cerebral infarction and the curative effect is significant.